The coexistence of asthma and COPD: risk factors, clinical history and lung function trajectories Source: Eur Respir J, 58 (5) 2004656; 10.1183/13993003.04656-2020 Year: 2021
Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes Source: Eur Respir J 2007; 30: 616-622 Year: 2007
The prognostic value of extended lung function characterization in COPD Source: Virtual Congress 2020 – Lung function tests and exhaled biomarkers Year: 2020
Outcomes and markers in the assessment of chronic obstructive pulmonary disease Source: Eur Respir J 2006; 27: 822-832 Year: 2006
Chronic respiratory symptoms but normal lung function: substantial disease burden but little evidence to inform practice Source: Eur Respir J, 54 (3) 1901363; 10.1183/13993003.01363-2019 Year: 2019
Influence of β2-adrenoceptor genotype on risk of asthma worsening using fluctuation analysis of lung function Source: Eur Respir J 2007; 30: Suppl. 51, 447s Year: 2007
Does rapid decline predict poor prognosis? Source: Annual Congress 2007 - Rapid decline in lung function and its consequences Year: 2007
Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients? Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017
Annual lung function changes in young patients with chronic lung disease Source: Eur Respir J 2002; 19: 886-891 Year: 2002
The positive effect of cilomilast on lung function in patients with chronic obstructive pulmonary disease (COPD) is independent of patient smoking status Source: Eur Respir J 2002; 20: Suppl. 38, 620s Year: 2002
Which markers other than FEV1 reflect disease progression in COPD? Source: Eur Respir J 2004; 24: Suppl. 48, 45s Year: 2004
Evidence for the onset of COPD in childhood, and the role of genetics Source: Annual Congress 2005 - Does COPD begin in childhood? Reviewing the evidence Year: 2005
Individual relationship between weather variables and lung function in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2005; 26: Suppl. 49, 385s Year: 2005
The interpretation and discriminatory power of bronchodilator measurements: the influence of baseline lung function and disease type Source: Eur Respir J 2003; 22: Suppl. 45, 276s Year: 2003
Risk factors for COPD spirometrically defined from the lower limit of normal in the BOLD project Source: Eur Respir J 2012; 39: 1343-1353 Year: 2012
The dynamic lung volume analysis in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2005; 26: Suppl. 49, 212s Year: 2005
Hoover‘s sign predicts expiratory flow limitation in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 807s Year: 2006
Simultaneous analysis of clinical markers for predicting increased lung function fluctability in stable asthma Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012
A new multidimensional model for predicting mortality in COPD: body mass index and FEV1 quotient/MRC dyspnoea score (SID) Source: Annual Congress 2006 - COPD – the challenges for primary care Year: 2006
Population surveillance in North West Adelaide: lung function and chronic obstructive pulmonary disease (COPD) across the diabetes spectrum Source: Annual Congress 2005 - Assessing the relevance of obstructive airway diseases Year: 2005